|
Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics
NU 2015-098B (NU 2015-098, NU 2018-036, NU 2025-036)
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
SHORT DESCRIPTION
MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders.
BACKGROUND
Leukemia and brain...
Published: 7/2/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, BIO2026, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted therapy, Therapeutics, TPD - Targeted protein degradation
Category(s): Life Sciences > Therapeutics
|
|
Compounds and methods for FBXW7-R465C-mediated protein degradation
NU 2024-224
INVENTORS
Xiaoyu Zhang*
Ananya Basu
SHORT DESCRIPTION
This invention describes novel heterobifunctional compounds that exploit a somatic mutant of the FBXW7 E3 ligase for targeted protein degradation.
BACKGROUND
Targeted protein degradation (TPD) is a powerful therapeutic strategy that harnesses the cell's natural machinery...
Published: 6/17/2026
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s): AUTM26C1, BIO2026, Cancer/Oncology, PROTAC, Targeted therapy, Therapeutics, TPD - Targeted protein degradation
Category(s): Life Sciences > Therapeutics
|
|
Compounds and methods of identifying novel E3 ligases for targeted protein degradation
NU 2023-096
INVENTORS
Ananya Angela Basu
Xiaoyu Zhang*
SHORT DESCRIPTION
A CRISPR-activation screen for discovering E3 ligases amenable to targeted protein degradation, and a novel PROTAC for FBXO22
BACKGROUND
Traditional small molecule drugs function by directly interfering with the activities of proteins. However, many proteins lack suitable...
Published: 6/17/2026
|
Updated: 3/29/2024
|
Inventor(s):
Keywords(s): AUTM26C1, BIO2026, Drug discovery, Proteomics, Small molecule, Targeted therapy, Therapeutics, TPD - Targeted protein degradation
Category(s): Life Sciences > Therapeutics
|